Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma
暂无分享,去创建一个
W. London | K. Janeway | H. Grier | Catherine M. Clinton | K. Ecklund | D. Swenson | Patricia T. Acharya | Lillian M. Guenther | D. Guo | M. Sridharan | R. G. Rowe | Stephanie C. Meyer | Dongjing Guo | Wendy B. London | Lillian M. Guenther | R. G. Rowe | Patricia T. Acharya | David W. Swenson | Catherine M. Clinton
[1] Response Evaluation Criteria in Solid Tumors , 2020, Definitions.
[2] D. Hawkins,et al. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P. Adamson,et al. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study , 2013, Pediatric blood & cancer.
[4] Paul A Meyers,et al. Outcome for adolescent and young adult patients with osteosarcoma , 2012, Cancer.
[5] J. Wathen,et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. , 2012, The oncologist.
[6] P. Adamson,et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study , 2010, Pediatric blood & cancer.
[7] K. Janeway,et al. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. , 2010, The Lancet. Oncology.
[8] P. Adamson,et al. Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group , 2010, Clinical Cancer Research.
[9] P. Harris,et al. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.
[10] L. Mirabello,et al. Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.
[11] S. Ferrari,et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. , 2005, European journal of cancer.
[12] E. Kleinerman,et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[14] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .
[15] M. Link,et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[17] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[18] J. Hermans,et al. Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy? , 1995, Clinical radiology.
[19] D. Vanel,et al. Osteosarcoma: chemotherapy-induced changes at MR imaging. , 1992, Radiology.
[20] J. Shuster,et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.
[21] R. Gelber,et al. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Rosen,et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy , 1982, Cancer.
[23] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[24] N. Jaffe,et al. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. , 2006, Journal of pediatric surgery.
[25] W. Winkelmann,et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Huvos,et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G Rosen,et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Varini,et al. High-dose ifosfamide in advanced osteosarcoma. , 1985, Cancer treatment reports.